Patient characteristics
| . | Haplo-HCT . | MSD HCT . | MUD TCD+ . | MUD TCD− . | P . |
|---|---|---|---|---|---|
| Patients, n | 237 | 911 | 468 | 326 | |
| Data source | <.001 | ||||
| CIBMTR | 104 (44) | 324 (36) | 156 (33) | 209 (64) | |
| EBMT | 133 (56) | 587 (64) | 312 (67) | 117 (36) | |
| Age, y | |||||
| Median, range | 54 (18-76) | 51 (18-77) | 53 (18-75) | 54 (18-74) | .004 |
| 60-69 | 51 (21) | 164 (18) | 126 (27) | 89 (27) | |
| ≥70 | 11 (5) | 8 (1) | 10 (2) | 6 (2) | |
| Males | 84 (35) | 322 (35) | 165 (35) | 119 (37) | .98 |
| KPS | |||||
| ≥90 | 131 (58) | 584 (68) | 301 (68) | 209 (65) | .03 |
| Not reported | 10 | 47 | 24 | 5 | |
| Cell source | <.001 | ||||
| Bone marrow | 74 (31) | 61 (7) | 26 (6) | 23 (7) | |
| Peripheral blood | 163 (69) | 850 (93) | 442 (94) | 303 (93) | |
| Conditioning intensity | <.001 | ||||
| Myeloablative | 65 (27) | 345 (38) | 154 (33) | 86 (27) | |
| RIC | 172 (73) | 552 (62) | 306 (67) | 239 (73) | |
| Missing data | 0 | 14 | 8 | 1 | |
| Disease status | .84 | ||||
| CR | 120 (51) | 451 (51) | 238 (52) | 161 (51) | |
| PR | 74 (32) | 252 (29) | 124 (27) | 96 (30) | |
| Resistant/Untreated | 39 (17) | 177 (20) | 93 (20) | 60 (19) | |
| Missing data | 4 | 31 | 13 | 9 | |
| HCT-CI | |||||
| ≥3 | 52 (28) | 191 (30) | 105 (35) | 95 (37) | .08 |
| Missing data* | 52 | 280 | 164 | 72 | |
| Chemotherapy lines | |||||
| Median (IQR), n | 2 (1.8-3) | 2 (1-3) | 2 (1-3) | 2 (2-3) | .34 |
| 1 line† | 31 (23) | 89 (26) | 57 (29) | 19 (21) | |
| 2 lines† | 47 (34) | 109 (32) | 62 (32) | 32 (34) | |
| ≥3 lines† | 58 (43) | 143 (42) | 76 (39) | 42 (45) | |
| Missing data‡ | 101 | 570 | 273 | 233 | |
| Female donor/male recipient | 61 (26) | 254 (28) | 52 (11) | 45 (14) | <.001 |
| Histology | .14 | ||||
| AITL | 68 (29) | 270 (30) | 155 (33) | 101 (31) | |
| ALCL§ | 58 (24) | 170 (19) | 82 (18) | 75 (23) | |
| PTCL | 111 (47) | 471 (51) | 231 (49) | 150 (46) | |
| Prior autologous HCT | 78 (33) | 336 (37) | 195 (42) | 132 (41) | .09 |
| Follow-up, median (range) [IQR], months | 24 (1-113) [13-48] | 43 (1-128) [17-72] | 35 (1-132) [13-63] | 49 (1-134) [24-72] |
| . | Haplo-HCT . | MSD HCT . | MUD TCD+ . | MUD TCD− . | P . |
|---|---|---|---|---|---|
| Patients, n | 237 | 911 | 468 | 326 | |
| Data source | <.001 | ||||
| CIBMTR | 104 (44) | 324 (36) | 156 (33) | 209 (64) | |
| EBMT | 133 (56) | 587 (64) | 312 (67) | 117 (36) | |
| Age, y | |||||
| Median, range | 54 (18-76) | 51 (18-77) | 53 (18-75) | 54 (18-74) | .004 |
| 60-69 | 51 (21) | 164 (18) | 126 (27) | 89 (27) | |
| ≥70 | 11 (5) | 8 (1) | 10 (2) | 6 (2) | |
| Males | 84 (35) | 322 (35) | 165 (35) | 119 (37) | .98 |
| KPS | |||||
| ≥90 | 131 (58) | 584 (68) | 301 (68) | 209 (65) | .03 |
| Not reported | 10 | 47 | 24 | 5 | |
| Cell source | <.001 | ||||
| Bone marrow | 74 (31) | 61 (7) | 26 (6) | 23 (7) | |
| Peripheral blood | 163 (69) | 850 (93) | 442 (94) | 303 (93) | |
| Conditioning intensity | <.001 | ||||
| Myeloablative | 65 (27) | 345 (38) | 154 (33) | 86 (27) | |
| RIC | 172 (73) | 552 (62) | 306 (67) | 239 (73) | |
| Missing data | 0 | 14 | 8 | 1 | |
| Disease status | .84 | ||||
| CR | 120 (51) | 451 (51) | 238 (52) | 161 (51) | |
| PR | 74 (32) | 252 (29) | 124 (27) | 96 (30) | |
| Resistant/Untreated | 39 (17) | 177 (20) | 93 (20) | 60 (19) | |
| Missing data | 4 | 31 | 13 | 9 | |
| HCT-CI | |||||
| ≥3 | 52 (28) | 191 (30) | 105 (35) | 95 (37) | .08 |
| Missing data* | 52 | 280 | 164 | 72 | |
| Chemotherapy lines | |||||
| Median (IQR), n | 2 (1.8-3) | 2 (1-3) | 2 (1-3) | 2 (2-3) | .34 |
| 1 line† | 31 (23) | 89 (26) | 57 (29) | 19 (21) | |
| 2 lines† | 47 (34) | 109 (32) | 62 (32) | 32 (34) | |
| ≥3 lines† | 58 (43) | 143 (42) | 76 (39) | 42 (45) | |
| Missing data‡ | 101 | 570 | 273 | 233 | |
| Female donor/male recipient | 61 (26) | 254 (28) | 52 (11) | 45 (14) | <.001 |
| Histology | .14 | ||||
| AITL | 68 (29) | 270 (30) | 155 (33) | 101 (31) | |
| ALCL§ | 58 (24) | 170 (19) | 82 (18) | 75 (23) | |
| PTCL | 111 (47) | 471 (51) | 231 (49) | 150 (46) | |
| Prior autologous HCT | 78 (33) | 336 (37) | 195 (42) | 132 (41) | .09 |
| Follow-up, median (range) [IQR], months | 24 (1-113) [13-48] | 43 (1-128) [17-72] | 35 (1-132) [13-63] | 49 (1-134) [24-72] |
Unless otherwise noted, data are n (%).
HCT-CI, HCT-comorbidity index; IQR, interquartile range; PR, partial response; PTCL, peripheral T-cell lymphoma.
EBMT does not collect this variable for Minimum Essential Data – A patients.
Missing number was excluded when calculating percentages.
CIBMTR does not collect this variable for the transplant-essential level patients.
ALCLs included 116 ALK+ cases, 143 ALK− cases, and 126 cases for which ALK status was not known.